Cargando…
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
INTRODUCTION: Over the last decade, the field of systems vaccinology has emerged, in which high throughput transcriptomics and other omics assays are used to probe changes of the innate and adaptive immune system in response to vaccination. The goal of this study was to benchmark key technical and a...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893923/ https://www.ncbi.nlm.nih.gov/pubmed/36741404 http://dx.doi.org/10.3389/fimmu.2022.1093242 |
_version_ | 1784881627136000000 |
---|---|
author | Goll, Johannes B. Bosinger, Steven E. Jensen, Travis L. Walum, Hasse Grimes, Tyler Tharp, Gregory K. Natrajan, Muktha S. Blazevic, Azra Head, Richard D. Gelber, Casey E. Steenbergen, Kristen J. Patel, Nirav B. Sanz, Patrick Rouphael, Nadine G. Anderson, Evan J. Mulligan, Mark J. Hoft, Daniel F. |
author_facet | Goll, Johannes B. Bosinger, Steven E. Jensen, Travis L. Walum, Hasse Grimes, Tyler Tharp, Gregory K. Natrajan, Muktha S. Blazevic, Azra Head, Richard D. Gelber, Casey E. Steenbergen, Kristen J. Patel, Nirav B. Sanz, Patrick Rouphael, Nadine G. Anderson, Evan J. Mulligan, Mark J. Hoft, Daniel F. |
author_sort | Goll, Johannes B. |
collection | PubMed |
description | INTRODUCTION: Over the last decade, the field of systems vaccinology has emerged, in which high throughput transcriptomics and other omics assays are used to probe changes of the innate and adaptive immune system in response to vaccination. The goal of this study was to benchmark key technical and analytical parameters of RNA sequencing (RNA-seq) in the context of a multi-site, double-blind randomized vaccine clinical trial. METHODS: We collected longitudinal peripheral blood mononuclear cell (PBMC) samples from 10 subjects before and after vaccination with a live attenuated Francisella tularensis vaccine and performed RNA-Seq at two different sites using aliquots from the same sample to generate two replicate datasets (5 time points for 50 samples each). We evaluated the impact of (i) filtering lowly-expressed genes, (ii) using external RNA controls, (iii) fold change and false discovery rate (FDR) filtering, (iv) read length, and (v) sequencing depth on differential expressed genes (DEGs) concordance between replicate datasets. Using synthetic mRNA spike-ins, we developed a method for empirically establishing minimal read-count thresholds for maintaining fold change accuracy on a per-experiment basis. We defined a reference PBMC transcriptome by pooling sequence data and established the impact of sequencing depth and gene filtering on transcriptome representation. Lastly, we modeled statistical power to detect DEGs for a range of sample sizes, effect sizes, and sequencing depths. RESULTS AND DISCUSSION: Our results showed that (i) filtering lowly-expressed genes is recommended to improve fold-change accuracy and inter-site agreement, if possible guided by mRNA spike-ins (ii) read length did not have a major impact on DEG detection, (iii) applying fold-change cutoffs for DEG detection reduced inter-set agreement and should be used with caution, if at all, (iv) reduction in sequencing depth had a minimal impact on statistical power but reduced the identifiable fraction of the PBMC transcriptome, (v) after sample size, effect size (i.e. the magnitude of fold change) was the most important driver of statistical power to detect DEG. The results from this study provide RNA sequencing benchmarks and guidelines for planning future similar vaccine studies. |
format | Online Article Text |
id | pubmed-9893923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98939232023-02-03 The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies Goll, Johannes B. Bosinger, Steven E. Jensen, Travis L. Walum, Hasse Grimes, Tyler Tharp, Gregory K. Natrajan, Muktha S. Blazevic, Azra Head, Richard D. Gelber, Casey E. Steenbergen, Kristen J. Patel, Nirav B. Sanz, Patrick Rouphael, Nadine G. Anderson, Evan J. Mulligan, Mark J. Hoft, Daniel F. Front Immunol Immunology INTRODUCTION: Over the last decade, the field of systems vaccinology has emerged, in which high throughput transcriptomics and other omics assays are used to probe changes of the innate and adaptive immune system in response to vaccination. The goal of this study was to benchmark key technical and analytical parameters of RNA sequencing (RNA-seq) in the context of a multi-site, double-blind randomized vaccine clinical trial. METHODS: We collected longitudinal peripheral blood mononuclear cell (PBMC) samples from 10 subjects before and after vaccination with a live attenuated Francisella tularensis vaccine and performed RNA-Seq at two different sites using aliquots from the same sample to generate two replicate datasets (5 time points for 50 samples each). We evaluated the impact of (i) filtering lowly-expressed genes, (ii) using external RNA controls, (iii) fold change and false discovery rate (FDR) filtering, (iv) read length, and (v) sequencing depth on differential expressed genes (DEGs) concordance between replicate datasets. Using synthetic mRNA spike-ins, we developed a method for empirically establishing minimal read-count thresholds for maintaining fold change accuracy on a per-experiment basis. We defined a reference PBMC transcriptome by pooling sequence data and established the impact of sequencing depth and gene filtering on transcriptome representation. Lastly, we modeled statistical power to detect DEGs for a range of sample sizes, effect sizes, and sequencing depths. RESULTS AND DISCUSSION: Our results showed that (i) filtering lowly-expressed genes is recommended to improve fold-change accuracy and inter-site agreement, if possible guided by mRNA spike-ins (ii) read length did not have a major impact on DEG detection, (iii) applying fold-change cutoffs for DEG detection reduced inter-set agreement and should be used with caution, if at all, (iv) reduction in sequencing depth had a minimal impact on statistical power but reduced the identifiable fraction of the PBMC transcriptome, (v) after sample size, effect size (i.e. the magnitude of fold change) was the most important driver of statistical power to detect DEG. The results from this study provide RNA sequencing benchmarks and guidelines for planning future similar vaccine studies. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9893923/ /pubmed/36741404 http://dx.doi.org/10.3389/fimmu.2022.1093242 Text en Copyright © 2023 Goll, Bosinger, Jensen, Walum, Grimes, Tharp, Natrajan, Blazevic, Head, Gelber, Steenbergen, Patel, Sanz, Rouphael, Anderson, Mulligan and Hoft https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Goll, Johannes B. Bosinger, Steven E. Jensen, Travis L. Walum, Hasse Grimes, Tyler Tharp, Gregory K. Natrajan, Muktha S. Blazevic, Azra Head, Richard D. Gelber, Casey E. Steenbergen, Kristen J. Patel, Nirav B. Sanz, Patrick Rouphael, Nadine G. Anderson, Evan J. Mulligan, Mark J. Hoft, Daniel F. The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies |
title | The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies |
title_full | The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies |
title_fullStr | The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies |
title_full_unstemmed | The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies |
title_short | The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies |
title_sort | vacc-seqqc project: benchmarking rna-seq for clinical vaccine studies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893923/ https://www.ncbi.nlm.nih.gov/pubmed/36741404 http://dx.doi.org/10.3389/fimmu.2022.1093242 |
work_keys_str_mv | AT golljohannesb thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT bosingerstevene thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT jensentravisl thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT walumhasse thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT grimestyler thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT tharpgregoryk thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT natrajanmukthas thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT blazevicazra thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT headrichardd thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT gelbercaseye thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT steenbergenkristenj thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT patelniravb thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT sanzpatrick thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT rouphaelnadineg thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT andersonevanj thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT mulliganmarkj thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT hoftdanielf thevaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT golljohannesb vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT bosingerstevene vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT jensentravisl vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT walumhasse vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT grimestyler vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT tharpgregoryk vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT natrajanmukthas vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT blazevicazra vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT headrichardd vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT gelbercaseye vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT steenbergenkristenj vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT patelniravb vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT sanzpatrick vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT rouphaelnadineg vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT andersonevanj vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT mulliganmarkj vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies AT hoftdanielf vaccseqqcprojectbenchmarkingrnaseqforclinicalvaccinestudies |